http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020068004-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fff83b1442a4fdf506529d977d1e4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab1e5b8825a61e050b6e3f95ba043c6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-074 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 |
| filingDate | 2019-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6532c4ca584332f77b27fbc2650e86b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e011182fce805cde03a4986fda4eb404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c2c10a46716a8ff525403739d817031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9129d6648fe9f5445f39171e6c91ded7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4501eea5bd80e958bc29659216ec9224 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe6a7f6590cd60bce1c599183ff22c65 |
| publicationDate | 2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020068004-A3 |
| titleOfInvention | Antituberculosis lanostane triterpenoid and method of making the compounds |
| abstract | A new lanostane triterpenoid (24E)-3β-acetoxy-15α-propionyloxylanosta-7,9( 11 ),24-trien-26-oic acid (GA003), is synthesized by acylation reaction of a naturally occurring fungal metabolite, (24 E )-3β-acetoxy-15α-hydroxylanosta-7,9( 11 ),24-trien-26-oic acid (ganoderic acid T-O). GA003 is identified as the most potent antimycobacterial against Mycobacterium tuberculosis H37Ra (MIC 0.0977 μ g/ml) through a series of structural modifications (semi-synthesis) of a lead natural product, (24 E )-3β,15α diacetoxylanosta-7,9(1 1),24-trien-26-oic acid. GA003 exhibits potent growth inhibitory activity against Mycobacterium tuberculosis strains H37Rv (virulent strain), THX-0001 (pre-XDR strain), THX-0002 (XDR strain), and THX-0003 (XDR strain), with MIC values of 0.3125, <0.156, 0.625, and 1.25 μ g/ml, respectively, while showing very weak cytotoxicity to Vero cells (African green monkey kidney fibroblasts). Therefore, GA003 and pharmaceutical compositions containing GA003 may be useful for the treatment of tuberculosis. |
| priorityDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.